« Return to News | CROs/Service Providers

CoreLab Partners opens office in Tokyo

Friday, January 20, 2012 02:50 PM

Signaling its plan to expand its business model in the Pacific Rim and build a global presence as a large imaging and cardiac safety core lab, CoreLab Partners is opening of an office in Tokyo under the wholly owned subsidiary CoreLab Partners Japan.

“This expanded presence is a natural extension of our geographic reach and global strategy to serve our growing base of multinational biopharma companies operating in the region and will complement our operational capability which was established in Shanghai, China over a decade ago,” said CoreLab Partners’ president and CEO, Dr. Mike Woehler. 

CoreLab Partners currently has a business alliance in Japan with Suzuken, which markets its cardiac safety services.

“CoreLabs has been present in the region since 1999 and has conducted hundreds of drug development studies in both cardiac safety and imaging for a variety of sponsor partners.  The addition of a local regional director and business development professional will allow CoreLab Partners to better service our client base by nurturing current relationships and opening up new markets for our full line of cardiac safety and imaging services” said Kevin Duffy, vice president, global business development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.